Literature DB >> 18474919

Calciphylaxis: the beginning of the end?

Adrian Fine1, Bunny Fontaine.   

Abstract

BACKGROUND: We previously reported a very high incidence of calciphylaxis, mainly in peritoneal dialysis (PD) patients. Although we identified several risk factors for the condition, including PD, we were unable to identify why our particular unit had such a high frequency of the condition and a reliable treatment.
OBJECTIVES: To assess the apparent changing frequency of the condition and the response to therapy, and to attempt to determine putative factors that might explain our uniquely high incidence of calciphylaxis.
METHODS: A prospective clinical record was kept on all patients that developed calciphylaxis in our center [both PD and hemodialysis (HD) units] between 1998 and 2006.
RESULTS: Of the 59 patients that developed calciphylaxis, 54 were on PD, 4 were on HD, and 1 was in predialysis. In the PD population, the mean yearly incidence from 1998 to 2003 was 4.5/100 patient-years, falling to 1.3/100 patient-years in 2004-2006. The percent of patients not taking calcium salts fell during this time period. Conversion to HD led to marked early improvement. A marked discrepancy between the levels of ionized calcium (routinely used in our center) and corrected serum calcium was found, with most cases of hypercalcemia (corrected) being missed by using ionized values.
CONCLUSIONS: The incidence of calciphylaxis is falling dramatically. This may be related partially to reduction in usage of calcium salts. Conversion to HD is beneficial. Our uniquely high incidence of calciphylaxis may be related to our use of ionized calcium levels to monitor these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474919

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  10 in total

1.  Chemical peritonitis after intraperitoneal sodium thiosulfate.

Authors:  D R Gupta; H Sangha; R Khanna
Journal:  Perit Dial Int       Date:  2012 Mar-Apr       Impact factor: 1.756

Review 2.  Calciphylaxis: risk factors, diagnosis, and treatment.

Authors:  Sagar U Nigwekar; Daniela Kroshinsky; Rosalynn M Nazarian; Jeremy Goverman; Rajeev Malhotra; Vicki Ann Jackson; Mihir M Kamdar; David J R Steele; Ravi I Thadhani
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

Review 3.  Sodium thiosulfate in the treatment of calcific uremic arteriolopathy.

Authors:  Georg Schlieper; Vincent Brandenburg; Markus Ketteler; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2009-09       Impact factor: 28.314

Review 4.  Calcific uremic arteriolopathy in end stage renal disease: pathophysiology and management.

Authors:  Preethi Yerram; Kunal Chaudhary
Journal:  Ochsner J       Date:  2014

5.  Treatment of severe metastatic calcification and calciphylaxis in dialysis patients.

Authors:  Saurabh K Goel; Keith Bellovich; Peter A McCullough
Journal:  Int J Nephrol       Date:  2011-02-24

6.  Calcific uremic arteriolopathy in peritoneal dialysis populations.

Authors:  Nicholas New; Janaki Mohandas; George T John; Sharad Ratanjee; Helen Healy; Leo Francis; Dwarakanathan Ranganathan
Journal:  Int J Nephrol       Date:  2011-06-27

7.  Multifactorial aetiology for non-uremic calciphylaxis: a case report.

Authors:  Sijan Basnet; Niranjan Tachamo; Rashmi Dhital; Biswaraj Tharu
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-06-12

8.  Development of the BWAT-CUA Scale to Assess Wounds in Patients with Calciphylaxis.

Authors:  Lisa J Gould; Thomas E Serena; Smeeta Sinha
Journal:  Diagnostics (Basel)       Date:  2021-04-20

9.  Calciphylaxis in peritoneal dialysis patients: a single center cohort study.

Authors:  Yanchen Zhang; Kristin M Corapi; Maria Luongo; Ravi Thadhani; Sagar U Nigwekar
Journal:  Int J Nephrol Renovasc Dis       Date:  2016-09-19

10.  Multi-intervention management of calcific uremic arteriolopathy in 24 patients.

Authors:  Claire Harris; Mercedeh Kiaii; Wynnie Lau; Myriam Farah
Journal:  Clin Kidney J       Date:  2018-03-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.